• 1
    Haller DG. New perspectives in the management of pancreas cancer. Semin Oncol. 2003; 30(4 Suppl 11 ): 310.
  • 2
    Fayad L, Keating MJ, Reuben JM, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001; 97: 256263.
  • 3
    Cortes J, Kurzrock R. Interleukin-10 in non-Hodgkin's lymphoma. Leuk Lymphoma. 1997; 26: 251259.
  • 4
    Gause A, Scholz R, Klein S, et al. Increased levels of circulating interleukin-6 in patients with Hodgkin's disease. Hematol Oncol. 1991; 9: 307313.
  • 5
    Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M. Serum interleukin-6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res. 1993; 53: 21182122.
  • 6
    Seymour JF, Talpaz M, Hagemeister FB, Cabanillas F, Kurzrock R. Clinical correlates of elevated serum levels of interleukin-6 in patients with untreated Hodgkin's disease. Am J Med. 1997; 102: 2128.
  • 7
    Fayad L, Cabanillas F, Talpaz M, McLaughlin P, Kurzrock R. High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphomas. Leuk Lymphoma. 1998; 30: 563571.
  • 8
    Blay JY, Negrier S, Combaret V, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal carcinoma. Cancer Res. 1992; 50: 33173322.
  • 9
    Nemunaitis J, Fong T, Shabe P, Martineau D, Ando D. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest. 2001; 19: 239247.
  • 10
    Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res. 1999; 5: 119127.
  • 11
    Xie K. Survey: interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 2001; 12: 375391.
  • 12
    Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol. 1995; 13: 575582.
  • 13
    Preti AH, Cabanillas F, Talpaz M, Tucker SL, Seymour JF, Kurzrock R. Prognostic value of serum interleukin-6 in diffuse large cell lymphomas. Ann Intern Med. 1997; 127: 186194.
  • 14
    Blay JY, Voorzanger N, Favrot M, Burdin N, Rousset F, Banchereau J. Presence of Epstein-Barr virus viral interleukin-10 in the serum of patients with non-human-immunodeficiency-virus-related diffuse large-cell non-Hodgkin's lymphomas. Blood. 1995; 86: 47024704.
  • 15
    Blay JY, Burdin N, Rousset F, et al. Serum interleukin-10 in non-Hodgkin's lymphomas: a prognostic factor. Blood. 1993; 82: 21692174.
  • 16
    Estrov Z, Kurzrock R, Wetzler M, et al. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. Blood. 1991; 78: 14761484.
  • 17
    Wetzler M, Kurzrock R, Estrov Z, et al. Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Blood. 1994; 84: 31423147.
  • 18
    Barnes PJ, Karin M. Nuclear factor-κB—a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997; 336: 10661071.
  • 19
    Daftarian PM, Kumar A, Kryworuchko M, Diaz-Mitoma F. IL-10 production is enhanced in human T cells by IL-12 and IL-6 and in monocytes by tumor necrosis factor-alpha. J Immunol. 1996; 157: 1220.
  • 20
    Blanchard JA II, Barve S, Joshi-Barve S, Talwalker R, Gates LK Jr. Cytokine production by CAPAN-1 and CAPAN-2 cell lines. Dig Dis Sci. 2000; 45: 927932.
  • 21
    Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995; 86: 12431254.
  • 22
    Freeman GJ, Freedman AS, Rabinowe SN, et al. Interleukin 6 gene expression in normal and neoplastic B cells. J Clin Invest. 1989; 83: 15121518.
  • 23
    Seymour JF, Kurzrock R. Interleukin-6: biologic properties and role in lymphoproliferative disorders. In: FreireichEJ, KantarjianHM, editors. Molecular genetics and therapy of leukemia. Boston: Kluwer Academic Publishers, 1996: 204217.
  • 24
    Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood. 1995; 85: 863872.
  • 25
    Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castelman's disease. Blood. 1989; 74: 13601367.
  • 26
    Woodroofe C, Muller W, Ruther U. Long-term consequences of interleukin-6 overexpression in transgenic mice. DNA Cell Biol. 1992; 11: 587592.
  • 27
    Scala G, Quinto I, Ruocco MR, et al. Expression of an exogenous interleukin 6 in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity. J Exp Med. 1990; 172: 6168.
  • 28
    Tosato G, Jones K, Breinig MK, McWilliams HP, McKnight JL. Interleukin-6 production in posttransplant lymphoproliferative disease. J Clin Invest. 1993; 91: 28062814.
  • 29
    Yee C, Blandi A, Wang XH, et al. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood. 1989; 74: 798804.
  • 30
    Twillie DA, Eisenberger MA, Carducce MA, Hseih WS, Kim WY, Simons JW. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology. 1995; 45: 542549.
  • 31
    Berek JS, Chung C, Kaidi K, Watson JM, Knox RM, Martinez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1991; 164: 10381043.
  • 32
    Ludwig H, Nachbaur DM, Fritz E, et al. Interleukin-6 is a prognostic factor in multiple myeloma. Blood. 1991; 77: 27942795.
  • 33
    Nachbaur DM, Herold M, Maneschg A, et al. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann Hematol. 1991; 62: 5458.
  • 34
    Chung YC, Chang YF. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol. 2003; 83: 222226.
  • 35
    Okada S, Okusaka T, Ishii H, et al. Elevated serum interleukin-6 levels in patients with pancreatic cancer. Jpn J Clin Oncol. 1998; 28: 1215.
  • 36
    Falconer JS, Fearon KC, Plester CE, Ross JA, Carter DC. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg. 1994; 219: 325331.
  • 37
    O'Riordain MG, Falconer JS, Maingay J, Fearon KC, Ross JA. Peripheral blood cells from weight-losing cancer patients control the hepatic acute phase response by a primarily interleukin-6 dependent mechanism. Int J Oncol. 1999; 15: 823827.
  • 38
    Opp M, Obal F, Cady AB, et al. Interleukin-6 is pyrogenic but not somnogenic. Physiol Behav. 1989; 45: 10691072.
  • 39
    Black K, Garrett IR, Mundy GR. Chinese hamster ovarian cells transfected with the murine interleukin-6 gene causes hypercalcemia as well as cachexia, leukocytosis, and thrombocytosis in tumor-bearing nude mice. Endocrinology. 1991; 128: 26572659.
  • 40
    Strassman G, Fong M, Kenney JS, et al. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest. 1992; 89: 16811684.
  • 41
    Weber J, Yang JC, Topalian SL, et al. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol. 1993; 11: 499506.
  • 42
    Mackiewicz A, Schooltink H, Heinrich PC, et al. Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol. 1992; 149: 20212027.
  • 43
    Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by the TH1 clones. J Exp Med. 1989; 170: 20812095.
  • 44
    Benjamin D, Knobloch TJ, Dayton MA. Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphomas constitutevely secrete large quantities of interleukin-10. Blood. 1992; 80: 12891298.
  • 45
    O'Garra A, Stapleton G, Dhar V, et al. Production of cytokines by mouse B-cells: lymphomas and normal B-cells produce interleukin 10. Int Immunol. 1990; 2: 821832.
  • 46
    O'Garra A, Chang R, Hastings R, Hastings R, Haughton G, Howard M. Ly-l B (B-1) cells are the main source of B-cell derived interleukin 10. Eur J Immunol. 1992; 22: 711717.
  • 47
    Go NF, Castle BE, Barrett R, et al. Interleukin 10, a novel B-cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. J Exp Med. 1990; 172: 16251631.
  • 48
    Rousset F, Garcia E, Defrance T, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A. 1992; 98: 18901893.
  • 49
    Thompson-Snipes L, Dhar V, Bond MW, Mosmann TR, Moore KW, Rennick DM. Interleukin 10: a novel stimulatory factor for mast cells and their progenitors. J Exp Med. 1991; 173: 507510.
  • 50
    Cortes JE, Talpaz M, Cabanillas F, Seymour JF, Kurzrock R. Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood. 1995; 85: 25162520.
  • 51
    Galizia G, Lieto E, DeVita F, et al. Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome. J Interferon Cytokine Res. 2002; 22: 473482.
  • 52
    Hatanaka H, Abe Y, Kamiya T, et al. Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann Oncol. 2000; 11: 815819.
  • 53
    Arend WP. The balance between IL-1 and IL1-Ra in disease. Cytokine Growth Factor Rev. 2002; 13: 323340.
  • 54
    Estrov Z, Kurzrock R, Estey E, et al. Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood. 1992; 79: 19381945.